Literature DB >> 7575701

Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.

S Patel1, D Pearson, D J Hosking.   

Abstract

OBJECTIVE: To assess the use of quantitative bone scanning (QBS) in the monitoring of patients with intravenous pamidronate-treated symptomatic monostotic Paget's disease of bone in whom biochemical markers of bone turnover are relatively normal.
METHODS: QBS was performed in 9 patients and the results were expressed as a ratio, obtained by comparing isotope uptake at an affected and a control (unaffected) site.
RESULTS: Serum alkaline phosphatase levels were normal in 7 of the 9 patients and changed minimally with treatment. The median QBS ratio was 2.72 (range 1.69-24.6) at baseline and 1.49 (range 0.63-4.18) posttreatment (P = 0.008). The median symptom score decreased with treatment, but QBS ratios provided the only objective measure of disease activity by which response to pamidronate therapy could be judged.
CONCLUSION: QBS may be a useful technique for evaluating the effects of treatment in patients with Paget's disease of bone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575701     DOI: 10.1002/art.1780381018

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.

Authors:  Kousei Yoh; Shinjiro Takata; Noriko Yoshimura; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2010-02-24       Impact factor: 2.626

Review 3.  Paget's disease of bone: diagnosis and management.

Authors:  D Hosking; P J Meunier; J D Ringe; J Y Reginster; C Gennari
Journal:  BMJ       Date:  1996-02-24

4.  Dynamic contrast-enhanced MRI for monitoring bisphosphonate therapy in Paget's disease of bone.

Authors:  Martin Libicher; C Kasperk; M Daniels-Wredenhagen; T Heye; H U Kauczor; P Nawroth; S Delorme; W Hosch
Journal:  Skeletal Radiol       Date:  2012-05-16       Impact factor: 2.199

5.  Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone.

Authors:  Owen Cronin; Laura Forsyth; Kirsteen Goodman; Steff C Lewis; Catriona Keerie; Allan Walker; Mary Porteous; Roseanne Cetnarskyj; Lakshminarayan R Ranganath; Peter L Selby; Geeta Hampson; Rama Chandra; Shu Ho; Jon H Tobias; Steven Young-Min; Malachi J McKenna; Rachel K Crowley; William D Fraser; Luigi Gennari; Ranuccio Nuti; Maria Luisa Brandi; Javier Del Pino-Montes; Jean-Pierre Devogelaer; Anne Durnez; Giancarlo Isaia; Marco Di Stefano; Núria Guañabens; Josep Blanch; Markus J Seibel; John P Walsh; Mark A Kotowicz; Geoffrey C Nicholson; Emma L Duncan; Gabor Major; Anne Horne; Nigel L Gilchrist; Maarten Boers; Gordon D Murray; Keith Charnock; Diana Wilkinson; R Graham G Russell; Stuart H Ralston
Journal:  BMJ Open       Date:  2019-09-04       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.